Navigation Links
SUPERA VERITAS® Receives Regulatory Approval in Australia
Date:4/28/2011

WEBSTER, Texas, April 28, 2011 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV) today announced the firm has received approval from the Therapeutic Goods Administration (TGA), Australia's regulatory agency for medical drugs and devices, for the SUPERA VERITAS® stent system for use in biliary and peripheral procedures.

"We are pleased to receive the TGA approval, and look forward to launching SUPERA VERITAS in the Australian market later this year," said Christopher Owens, President and CEO of IDEV.  "Australia represents a leading market in the Asia-Pacific region, and we have established a wholly owned subsidiary, IDEV Medical Technologies PTY LTD, in Sydney to support the product registration and introduction of this unique next generation technology.  This is the first in a series of steps to extend our global footprint as well as our growth strategy in the Asia-Pacific region."

Australia represents an established growing peripheral vascular stent market, with an experienced base of endovascular physicians.

The SUPERA stent has been recognized as a different class of stent, based on proprietary technology and mechanical properties that result in unmatched radial strength and flexibility.  It provides a new treatment option for patients with biliary strictures or peripheral arterial disease (PAD).

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.  For more information please visit www.idevmd.com.

The SUPERA stent is currently indicated in the U.S. for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe, Canada and Australia for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).Contact:

Donna LucchesiVice President Global MarketingIDEV Technologies, Incorporated(281) 525-2000
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITAS®
2. One-Year European Registry Data Released for Popliteal Stenting With SUPERA®
3. Long-Term European Data Released for SUPERA® Stent from IDEV Technologies
4. IDEV Technologies Announces FDA 510(k) Clearance for SUPERA VERITAS™
5. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
6. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
7. MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
8. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
9. STAAR Surgicals nanoFLEX™ Collamer® IOL Receives CE Mark Approval
10. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
11. Sound Surgical Technologies PowerX™ Lipo System Receives Clearance from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):